title: Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869.
abstract: This report describes a companion flow cytometry study (Cancer and Leukemia Group B (CALGB)--8869) using tumors derived from patients enrolled in a large randomized clinical trial (CALGB-8541) performed on 1,572 patients with early stage, node-positive breast cancer. The CALGB initiated an adjuvant breast cancer trial in 1985 to determine if dose intensification (dose of drug per unit time) of chemotherapy was related to relapse-free and overall survival. Patients were randomized by pretreatment clinical variables to one of three different dosage regimens of chemotherapy. Using a tumor enrichment procedure, 442 paraffin-embedded blocks were analyzed by flow cytometry, and S-phase fraction (SPF) was analyzed by three different methods. Ploidy analysis was performed using standard procedures. Tissue from 90% of the patients was suitable for ploidy analysis, whereas only 68% could be assessed for SPF. With a median follow-up time of 80 months, our results show that ploidy status had no clinical utility, whereas high SPF predicted poorer overall survival. The rectangular fit model for SPF was more predictive of outcome than both the area fit model and a computer fit model (modfit) for SPF. In univariate analysis, patients with a low SPF (< 10%) had a better prognosis than those patients with a high SPF (> 10%), but they responded equally well to the different treatment regimens. Patients with high SPF (> 10%) had longer relapse-free and overall survival to high dose chemotherapy compared to low or standard dose chemotherapy. Multivariate analysis indicated that treatment intensity as well as the number of positive nodes, tumor size, steroid receptor status, and c-erb B-2 expression were significant in predicting overall and disease-free survival. The multivariate analysis, however, revealed that SPF was significant in predicting overall but not disease-free survival, but there was no longer any relationship among SPF, dose intensity, and outcome.
authors: Bowman Gray School of Medicine, Winston-Salem, North Carolina, USA.
authors: T E
authors: TE
authors: Kute
authors: Y
authors: Y
authors: Quadri
authors: H
authors: H
authors: Muss
authors: N
authors: N
authors: Zbieranski
authors: C
authors: C
authors: Cirrincione
authors: D A
authors: DA
authors: Berry
authors: M
authors: M
authors: Barcos
authors: A P
authors: AP
authors: Thor
authors: E
authors: E
authors: Liu
authors: F
authors: F
authors: Koerner
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D002453:Cell Cycle / Q000235:genetics; D004358:Drug Therapy; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007700:Kinetics; D007938:Leukemia / Q000628:therapy*; D011003:Ploidies; D011237:Predictive Value of Tests; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D016196:S Phase / Q000235:genetics; D015996:Survival Rate